Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Trial group treated with pantaprazole once a day for five days and amoxicillin 1 g twice a day and next 5 days they treated with the same dose of pantaprazole and levofloxacin 500 mg d
Treatment - Drugs
Trial group treated with pantaprazole once a day for five days and amoxicillin 1 g twice a day and next 5 days they treated with the same dose of pantaprazole and levofloxacin 500 mg daily and tinidaz
group II (control) treated with pantaprazole 40 mg daily, clarithromycin 500 mg twice a day and amoxicillin 1 g twice a day and metronidazole 500 mg twice a day for 14 days.
Sponsors
Vice chancellor for research,Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients over seventeen years, admitted to the infectious diseases clinics in Firoozgar hospital; the presence of H. pylori in the presence of gastritis or peptic ulcer specimens obtained by endoscopy and rapid urease test. Exclusion criteria: pregnant or lactating women; having chronic illness, such as cancer ( Especially gastrointestinal cancer ) , liver and kidney failure; positive history of antibiotic use in the two weeks prior to admission; no history of allergy to the antibiotics studied.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urease Breath Test. Timepoint: one month after finishing of treatment. Method of measurement: The presence of H. pylori in the stomach by using carbon 13-labeled urea fed to the patient and the patient's breathing carbon measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Daneshbodi
Medical university of Iran university
Outcome results
None listed